GXO Logistics (GXO) Q3 2025 earnings review
Record Revenue and Strong Wins Mask Flat EPS; New CEO Prioritizes Growth
GXO Logistics reported record Q3 revenue of $3.4 billion, up 8% YoY, with Adjusted EBITDA growing 13%. However, the strong top-line and operational performance did not translate to the bottom line, as Adjusted Diluted EPS remained flat YoY at $0.79. The quarter was marked by a significant acceleration in new business wins (+24% YoY to $280M), providing strong visibility into 2026. On his first earnings call, new CEO Patrick Kelleher outlined a clear agenda to accelerate organic growth, particularly in North America, and expand margins. The company reaffirmed its full-year 2025 guidance.
🐂 Bull Case
New business wins grew 24% YoY to $280 million, bringing the YTD total to over $800 million. The company has already secured nearly $700 million in incremental revenue for 2026, a 50% increase compared to this time last year.
New CEO Patrick Kelleher has clearly prioritized accelerating organic growth and margin expansion, with a specific focus on the $250 billion North American market. The appointment of a new regional president signals a renewed push in this key geography.
The integration is progressing well, with synergy realization on track and teams already collaborating on tenders. This acquisition is set to unlock growth in high-value industrial and aerospace sectors across Europe.
🐻 Bear Case
Despite a 13% increase in Adjusted EBITDA, Adjusted Diluted EPS was flat year-over-year. This indicates that operational gains are not fully translating to shareholder earnings, with adjusted net income slightly declining.
Organic revenue growth decelerated to 3.9% from 5.6% in the prior quarter. Management commentary about 'softer trends in volumes' continuing into Q4 suggests potential macroeconomic headwinds for existing customers.
⚖️ Verdict: 🟢
Bullish. The flat EPS is a notable blemish, but the powerful acceleration in new business wins and the clear, aggressive growth strategy articulated by the new CEO are more significant forward-looking indicators. The company is successfully diversifying into high-growth verticals, and with the Wincanton integration on track, the foundation is being set for future growth and margin expansion.
Key Themes
New CEO Prioritizes North American Growth and Margin Expansion
On his first call, CEO Patrick Kelleher outlined a clear strategy to accelerate profitable growth. The primary focus is the North American market, a $250B+ opportunity where GXO is underpenetrated. He has already appointed a new President for the Americas & APAC region and is recruiting for COO and CCO roles to sharpen global execution and drive organic growth. He also sees a 'structural margin opportunity' through a focus on higher-margin verticals, leveraging technology for labor productivity, and ongoing cost discipline.
High-Growth Verticals Gaining Significant Traction
GXO's strategic push into less cyclical, high-growth sectors is showing strong results. The sales pipeline in Life Sciences and Aerospace & Defense each grew 30% quarter-over-quarter, while the Technology pipeline tripled. Key milestones include the flawless launch of the landmark NHS contract in the UK, new contracts with a leading hyperscaler in the data center space, and expanded partnerships with Boeing and NetApp.
Margin Recovery and Sequential Improvement
Adjusted EBITDA margin expanded to 7.4%, up 30 basis points YoY and 100 basis points sequentially from 6.4% in Q2. Management attributed the improvement to enhanced site-level productivity and the maturation of large, automated contracts that are ramping up faster than expected. This demonstrates progress in translating operational efficiency into improved profitability.
Flat Earnings Per Share Contradicts Positive Narrative
A key concern is the disconnect between strong operational growth and shareholder returns. While Adjusted EBITDA rose 13% YoY, Adjusted Diluted EPS was flat at $0.79. This was driven by a slight decline in Adjusted Net Income to $91 million from $95 million in the prior year, with share buybacks being the primary reason EPS did not decline. This suggests higher interest, tax, or other costs are offsetting operational gains before they reach the bottom line.
Organic Growth Decelerated Sequentially
While YoY organic growth of 3.9% was solid, it represents a notable deceleration from the 5.6% achieved in Q2 2025. Management commentary in the earnings call points to expectations of 'softer trends in volumes to continue' in Q4, signaling that the underlying macroeconomic environment for existing customer volumes remains challenging, even as new contract wins accelerate.
Other KPIs
Reversing. After two consecutive quarters of negative cash flow, GXO generated a robust $187 million in FCF. This strong performance puts the company on track to achieve its full-year target for adjusted EBITDA to free cash flow conversion of 25% to 35%, demonstrating disciplined capital and working capital management.
Accelerating. New contract wins were up 24% year-over-year. This strong commercial performance brings year-to-date wins to over $800 million and provides confidence in the company's ability to exceed $1 billion in new wins for 2025.
Stable. The net debt to adjusted EBITDA ratio improved to 2.7x, demonstrating progress in deleveraging the balance sheet following recent acquisitions. Management remains focused on disciplined capital allocation, prioritizing organic growth investments and further deleveraging.
Guidance
The company reaffirmed its full-year 2025 guidance across all metrics, reflecting confidence in its operating performance year-to-date and visibility into Q4.
Implies acceleration. With year-to-date organic growth at 4.1%, the guidance implies an acceleration in Q4 to a range of approximately 1.5% to 11.0%. The midpoint of 5.0% suggests Q4 growth around 7.5%, driven by the ramp-up of major new contracts like NHS, which is expected to offset softer underlying volumes.
Implies stability/slight deceleration. Year-to-date adjusted EBITDA is $626M. The guidance midpoint of $875M implies a Q4 result of approximately $249M. This would be slightly down from both Q3 2025 ($251M) and Q4 2024 ($251M), reflecting what management called 'harder comparisons' and a 'more muted' margin performance in the final quarter.
Key Questions
Bridging the EPS Gap
Adjusted EBITDA grew a strong 13% year-over-year, but Adjusted EPS was flat. Can you provide a more detailed bridge for this discrepancy and explain why the strong operational leverage is not flowing through to the bottom line?
Underlying Volume Trends
Organic growth decelerated sequentially, and you've mentioned 'softer trends in volumes' continuing. Can you quantify what you are seeing from existing customers versus the contribution from new contract ramps, and what is your baseline assumption for underlying volumes in the Q4 guidance?
North American Acceleration Plan
Patrick, you've highlighted North America as a key priority. Beyond the recent leadership change, what are the top two or three specific operational or commercial changes you plan to implement in the next six months to accelerate growth in this market?